KYMR Stock Forecast: Kymera Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$115
−3.50% on the day

The 24 Wall Street analysts covering Kymera Therapeutics, Inc. hold a median 12-month price target of $144 — +25.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 65 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$10.2B
Ticker Nerd rank
65/ 100
Median analyst target
$144
Analysts covering
24
Revenue$65.0M+466.4% y/y
Operating income−$75.6M
Net income−$61.2M
Free cash flow−$54.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.7%
1M
+1.5%
YTD
+48.1%
1Y
+78.3%
From 52W high
−17.0%
From 52W low
+79.3%
$64
$139
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Kymera Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
65/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
97
Value
84
Growth
77
Quality
72
Volatility
70
Revisions
42
Issuance
41
Accruals
31

Momentum (97): The shares have been drifting up relative to others.

Accruals (31): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

KYMR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KYMR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$80$100$120$140$160$180Jan 26Apr 26Jul 26Oct 26KYMRHigh $180Median $144Low $116

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says24 analysts
22
Buy
2
Hold
0
Sell
$116
Low
$144
Median
$180
High

The green dot is the last close — the median target sits +25.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 14 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
2 Nov 2026BarclaysMaintainsOverweight$139 → $170
30 Oct 2026RBC CapitalMaintainsSector Perform$112 → $116
30 Oct 2026Truist SecuritiesReiteratesBuy$136 → $150
29 Oct 2026BTIGMaintainsBuy$134 → $139
27 Oct 2026Morgan StanleyMaintainsOverweight$135 → $146
9 Oct 2026Raymond JamesInitiatesOutperform$140
5 Oct 2026CitigroupMaintainsBuy$135 → $150
22 Sept 2026StifelMaintainsBuy$132 → $152
14 Sept 2026B of A SecuritiesMaintainsBuy$123 → $144
10 Sept 2026Wolfe ResearchUpgradeOutperform—
31 Aug 2026GuggenheimMaintainsBuy$135 → $170
27 Aug 2026Wells FargoMaintainsOverweight$116 → $151
6 Aug 2026BarclaysMaintainsOverweight$133 → $139
30 July 2026Deutsche BankInitiatesHold$120
28 July 2026GuggenheimMaintainsBuy$125 → $135
16 July 2026MizuhoMaintainsOutperform$120 → $140
13 July 2026RBC CapitalDowngradeSector Perform$106 → $115
30 June 2026B of A SecuritiesMaintainsBuy—
29 June 2026B. Riley SecuritiesMaintainsBuy—
29 June 2026Truist SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for KYMR.

Market Radar

This page is one stock. Monday covers all of them.

KYMR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

KYMR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Kymera Therapeutics, Inc. returned +78.3% against +6.9% for the S&P 500, dividends included.

KYMR vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180200Jan 26Apr 26Jul 26Oct 26KYMRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KYMR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
8
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
97.6×

Cheaper than 3% of US stocks

Price / book
6.2×

Cheaper than 14% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−27.3%

Higher than 29% of US stocks

Return on assets
−17.6%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kymera Therapeutics, Inc. has a market value of $10.2B and an enterprise value of $9.3B.

  • Revenue in the twelve months to 30 June 2026: $105.0M. The latest quarter grew 466.4% year on year.

  • Net income over the same four quarters: −$299.6M, a −285.3% net margin.

  • Diluted earnings per share, trailing twelve months: −$3.24.

  • Free cash flow in the twelve months to 30 June 2026: −$238.0M.

  • Shares outstanding: 82.8M.

  • Kymera Therapeutics, Inc. employs 285 people — $368K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

KYMR and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KYMRKymera Therapeutics, Inc.$10.2B65
KRYSKrystal Biotech, Inc.$9.1B83
TGTXTG Therapeutics, Inc.$10.1B78
HALOHalozyme Therapeutics, Inc.$10.4B96
PCVXVaxcyte, Inc.$8.7B46
MDGLMadrigal Pharmaceuticals, Inc.$8.7B79
SYRESpyre Therapeutics, Inc.$8.6B33

Take a look at KYMR’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Kymera Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about KYMR

What is the KYMR stock price forecast for 2026-2027?

The 24 Wall Street analysts covering Kymera Therapeutics, Inc. have a median 12-month price target of $144, with estimates ranging from $116 to $180. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KYMR stock a buy right now?

Of the 24 analysts covering Kymera Therapeutics, Inc., 22 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kymera Therapeutics, Inc. 65 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KYMR?

As at 21 Nov 2026, Kymera Therapeutics, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).

Will KYMR stock go up?

No one can know that. What the data says: the median 12-month target from 24 analysts implies +25.0% from the last close, and Ticker Nerd's factor model ranks Kymera Therapeutics, Inc. 65 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KYMR stock forecast for 2030?

No analyst covering Kymera Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KYMR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $116 to $180 over the next 12 months.

How has KYMR stock performed over the past year?

Kymera Therapeutics, Inc. returned +78.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kymera Therapeutics, Inc. do?

Kymera Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule medicines that use targeted protein degradation to address disease-causing proteins. The company’s work centers on harnessing the body’s natural protein recycling systems to create oral therapies designed for conditions that are difficult to treat with conventional approaches.

Company

About Kymera Therapeutics, Inc.

Kymera Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule medicines that use targeted protein degradation to address disease-causing proteins. The company’s work centers on harnessing the body’s natural protein recycling systems to create oral therapies designed for conditions that are difficult to treat with conventional approaches. Its current programs span immunology, inflammation, and oncology, with research aimed at diseases such as atopic dermatitis, hidradenitis suppurativa, autoimmune disorders, and certain cancers. Kymera Therapeutics Inc. operates through a differentiated drug-discovery platform that supports both internal pipeline development and strategic research collaborations. Headquartered in Watertown, Massachusetts, the company plays a specialized role in the biotechnology market by advancing novel treatment approaches for serious diseases.

CEO Dr. Nello Mainolfi M.D., Ph.D. · 285 employees · United States · https://www.kymeratx.com